MC
KYMR icon

Merck & Co’s Kymera Therapeutics KYMR Stock Holding History

Merck & Co’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$88.5M Hold
772,165
– – 16.82% 3
2026
Q1 		$64.3M Hold
772,165
– – 18.4% 3
2025
Q4 		$60.1M Hold
772,165
– – 21.75% 3
2025
Q3 		$43.7M Hold
772,165
– – 19.17% 3
2025
Q2 		$33.7M Hold
772,165
– – 15.63% 3
2025
Q1 		$21.1M Hold
772,165
– – 12.86% 3
2024
Q4 		$31.1M Buy
+772,165
New +$34.9M 12.04% 3

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Merck & Co's KYMR Position: Q2 2026 in Review

Merck & Co held its Kymera Therapeutics (KYMR) position steady in Q2 2026 at 772,165 shares worth $88.5M. The position accounts for 16.82% of the portfolio, ranked #3.

Merck & Co first reported a position in KYMR in Q4 2024 and has held it in 7 quarters since. 276 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • Merck & Co held 772,165 shares of Kymera Therapeutics worth $88.5M as of Q2 2026.
  • Merck & Co left its Kymera Therapeutics share count unchanged in Q2 2026.
  • Kymera Therapeutics made up 16.82% of Merck & Co's portfolio in Q2 2026, its #3 holding.
  • Merck & Co first reported a position in Kymera Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 276 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Merck & Co's 13F filing for Q2 2026, filed 7 Aug 2026.